Synthesis, In Silico, and Biological Evaluation of Non-Hydroxamate Benzoic Acid-Based Derivatives as Potential Histone Deacetylase Inhibitors (HDACi).

ABSTRACT: Unregulated epigenetic modifications, including histone acetylation/deacetylation mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), contribute to cancer progression. HDACs, often overexpressed in cancer, downregulate tumor suppressor genes, making them crucial targets for treatment. This work aimed to develop non-hydroxamate benzoic acid-based HDAC inhibitors (HDACi) with comparable effect to the currently four FDA-approved HDACi, which are known for their poor solubility, poor distribution, and significant side effects. All compounds were structurally verified using FTIR, ¹HNMR, ¹³CNMR, and mass spectrometry. In silico analysis showed that compound A3bn (3-chloro-4-((2-(2-(4-hydroxybenzylidene) hydrazinyl)-2-oxoethyl)amino)benzoic acid)

SUBMITTER: Al Rahim NAA 

PROVIDER: S-EPMC12716022 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature